# RMC-9805-001 (NCT06040541)

> Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06040541
- Phase: PHASE1
- Status: RECRUITING
- Sponsor: Revolution Medicines, Inc.
- Conditions: Non-small Cell Lung Cancer (NSCLC); Colorectal Cancer (CRC); Pancreatic Ductal Adenocarcinoma (PDAC); Advanced Solid Tumors
- Interventions: RMC-9805; RMC-6236
- Enrollment: 604
- Primary outcome: Adverse events
- Primary outcome: Dose Limiting Toxicities

## Indexed commentary on RMC-9805-001 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 11
- YouTube: 1
- Bluesky threads: 1

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=rmc-9805-001-nct06040541

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT06040541", "email": "<work email>"}; the inbox owner confirms by the emailed link.